The first such product that Cobra will develop will be Lovaxin C, Advaxis’ therapeutic vaccine for the treatment of cervical and head and neck cancers that will be entering a phase I/II study in cervical cancer patients this year.
The new agreement supersedes a prior agreement and provides for mutual exclusivity, priority of supply, collaboration on regulatory issues, R&D of manufacturing processes that have already resulted in new intellectual property owned by Advaxis, and the long-term supply of live Listeria based vaccines on a discounted basis.
“We are delighted that Advaxis has decided to broaden the relationship with Cobra and make us an exclusive vaccine supplier not only for Lovaxin C, but also for its other Listeria cancer vaccines,” David Thatcher, chief executive of Cobra Biomanufacturing “We intend for this to be a long-term relationship, providing the Advaxis cancer vaccines from preclinical to commercial supply.”